Summit Therapeutics To Discontinue Ezutromid Development - Quick Facts

Summit Therapeutics plc (SMMT) announced PhaseOut DMD has not met its primary or secondary endpoints after 48 weeks of treatment of ezutromid in patients with Duchenne muscular dystrophy. PhaseOut DMD was a multi-centre, open-label Phase 2 clinical trial of the utrophin modulator, ezutromid. The company said it is discontinuing the development of ezutromid and as a result, will be implementing cost reduction measures. Summit will now focus its operations on the development of its pipeline of new mechanism antibiotics.

The company noted that its lead product candidate, ridinilazole, is expected to enter Phase 3 clinical trials for the treatment of C. difficile infection in first-quarter 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Bank of America Corp. (BAC) reported Thursday that net income applicable to common shareholders for the fourth quarter grew 30 percent to $6.77 billion from last year's $5.21 billion, with earnings per share increasing to $0.82 from $0.59 in the prior year, reflecting strong operating leverage as revenues... Shares of ASML Holding N.V. were gaining more than 1 percent in Amsterdam trading after the Dutch semiconductor equipment maker reported Wednesday higher profit and net sales in its fourth quarter. The company also projects higher sales in fiscal 2022, and a 100 percent increase in total dividend. Coffee giant Starbucks has expanded its delivery and online services in China through a partnership with e-commerce platform for services, Meituan. The three new and expanded services in offer would allow customers to connect with their local stores as well as curate an individual Starbucks Experience both online and offline.
Follow RTT